NCT01721941View on ClinicalTrials.gov

TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma

PHASE1UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2016

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Phase I Dose level -1

The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).

DRUG

Phase I dose level 1

The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).

DRUG

Phase I Dose level 2

The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).

DRUG

Phase I Dose level 3

The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).

Trial Locations (1)

92037

Scripps Clinic, La Jolla

Sponsors

Collaborators (1)

Threshold Pharmaceuticals
All Listed Sponsors
collaborator

Threshold Pharmaceuticals

INDUSTRY

lead

Scripps Clinic Cancer Center

OTHER

NCT01721941 - TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter